Geffrey Alexandra L, Belt Olivia D, Paolini Jan L, Thiele Elizabeth A
Herscot Center for Tuberous Sclerosis Complex, Massachusetts General Hospital, 175 Cambridge Street, Suite 340, Boston, MA 02114, United States.
Herscot Center for Tuberous Sclerosis Complex, Massachusetts General Hospital, 175 Cambridge Street, Suite 340, Boston, MA 02114, United States.
Epilepsy Res. 2015 May;112:72-5. doi: 10.1016/j.eplepsyres.2015.02.008. Epub 2015 Feb 16.
Lacosamide (LCS) was approved by the United States Food and Drug Administration (FDA) in 2008 as adjunctive therapy to other anti-epileptic drugs (AEDs) to treat focal-onset seizures, with or without secondary generalization. Its role in the treatment of epilepsy in individuals with tuberous sclerosis complex (TSC) has yet to be determined. This study evaluates LCS treatment of focal-onset refractory epilepsy in patients with TSC. From November 2009 to June 2014, 46 TSC patients followed by a single neurologist were treated with LCS. Forty-eight percent were responders (seizure reduction ≥50%). No significant differences between responders and non-responders in demographic characteristics were found. LCS appears to be an effective and safe treatment of refractory focal onset seizures in TSC. Determining the long-term tolerability and efficacy of LCS in TSC patients requires additional clinical experience.
拉科酰胺（LCS）于2008年被美国食品药品监督管理局（FDA）批准作为其他抗癫痫药物（AEDs）的辅助疗法，用于治疗局灶性发作，不论是否伴有继发性全面发作。其在结节性硬化症（TSC）患者癫痫治疗中的作用尚未确定。本研究评估LCS对TSC患者局灶性发作难治性癫痫的治疗效果。2009年11月至2014年6月，46例由单一神经科医生随访的TSC患者接受了LCS治疗。48%的患者有反应（癫痫发作减少≥50%）。在人口统计学特征方面，有反应者和无反应者之间未发现显著差异。LCS似乎是治疗TSC患者难治性局灶性发作的一种有效且安全的疗法。确定LCS在TSC患者中的长期耐受性和疗效需要更多的临床经验。
